What does ITI mean in THERAPEUTICS

Immunomic Therapeutics Inc. (ITI) is a clinical-stage biotechnology company dedicated to developing novel immunotherapies for the treatment of cancer. ITI's research focuses on tumor-specific antigens, immune checkpoint inhibitors, and oncolytic viruses to enhance the immune system's ability to recognize and eliminate cancer cells.

ITI's pipeline includes several promising drug candidates, including:

• IMT-001: A tumor-specific antigen vaccine targeting the Wilms' tumor 1 (WT1) protein, commonly expressed in various cancers.
• IMT-002: An oncolytic virus that selectively targets and destroys cancer cells while stimulating the immune system.
• IMT-003: A combination therapy of IMT-001 and IMT-002, designed to enhance antitumor effects and improve patient outcomes.

ITI is conducting several clinical trials to evaluate the safety and efficacy of its drug candidates. Phase 2 trials of IMT-001 in acute myeloid leukemia (AML) and multiple myeloma (MM) are ongoing, with promising preliminary results. Phase 1/2 trials of IMT-002 in solid tumors and hematologic malignancies are also underway.

ITI's immunotherapies aim to provide several potential benefits:

• Enhanced tumor cell recognition and elimination by the immune system.
• Reduced tumor burden and improved disease control.
• Durable antitumor responses, potentially leading to long-term remission.
• Reduced side effects compared to traditional cancer treatments.

ITI's pipeline of innovative immunotherapies, combined with its experienced research and development team, positions the company well for future growth. The ongoing clinical trials hold the potential to demonstrate the efficacy of ITI's drug candidates, leading to regulatory approvals and commercialization. ITI's commitment to advancing cancer immunotherapy is expected to drive continued progress and contribute to improved patient outcomes.